Navigation Links
Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model
Date:4/22/2009

-Preclinical Results Further Validate Significant Anti-Tumor Potential of Fully Human Anti-PS Antibodies and Expand the Company's PS-Targeting Platform-

-Treatment with Mouse Equivalent to the Human Antibody Inhibited Tumor Growth in a Prostate Cancer Model by More than 90%-

DENVER and TUSTIN, Calif., April 22 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today announced that preclinical data presented during the AACR 100th Annual Meeting 2009 shows that one of its fully human phosphatidylserine (PS)-targeting antibodies demonstrated encouraging signs of efficacy in a preclinical model of prostate cancer. These positive new data validate the anti-tumor potential of this human anti-PS antibody, which is similar to Peregrine's lead clinical stage antibody bavituximab and extends Peregrine's anti-PS antibody pipeline. Bavituximab is in Phase II clinical trials for the treatment of advanced breast cancer and non-small cell lung cancer.

Peregrine's PS-targeting antibodies bind to the cellular membrane component PS that is usually located inside cells, but which becomes exposed on the external surface of the cells that line the blood vessels of tumors (the tumor vascular endothelium), creating a specific target for anti-cancer treatments. By binding to PS, the antibodies are believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels.

In today's presentation, researchers from UT Southwestern Medical Center in Dallas and Affitech A/S reported that similar to bavituximab, the human antibody PGN635 targets and binds specifically to the tumor vascular endothelium(1). Treatment with androgen deprivation therapy or docetaxel substantially increased the percentage
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... 2014. Total revenues were $4.3 million for the three ... months ended December 31, 2013.  Net loss was $5.9 ... as compared to a net loss of $5.1 million ... million and net loss was $22.1 million for the ...
(Date:3/2/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... year ended December 31, 2014. Financial highlights for the fourth ... of $5.3 million, or $0.04 per share. This compares to ... million, or $0.19 per share, for the fourth quarter of ... of $75.3 million and a net loss of $68.4 million, ...
(Date:3/2/2015)... -- Vivex Biomedical, Inc., a leading processor of human tissue, ... that it hired Lou Barnes as President ... Biomedical formed UMTB Biomedical as a wholly-owned subsidiary to ... November 2014. UMTB is the oldest tissue bank in ... year veteran of the tissue banking industry, having most ...
Breaking Medicine Technology:DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 3DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 4DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 5DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 6DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 7DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 8DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 9DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 10DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 11DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 12Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 2Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 3
... June 20, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... subsidiary, Watson Laboratories, Inc. – Florida, filed an ... Food and Drug Administration (FDA) seeking approval to ... product is a generic version of GlaxoSmithKline,s AVODART(R), ...
... Findings from three studies conducted by the U.S. Food ... conveyed and displayed in printed drug advertising affects consumer ... ) The studies, designed by experts ... (DDMAC) in the Center for Drug Evaluation and Research, ...
Cached Medicine Technology:Watson Confirms AVODART(R) Patent Challenge 2FDA Examines Ways to Improve Consumer Understanding of Prescription Drug Ads 2FDA Examines Ways to Improve Consumer Understanding of Prescription Drug Ads 3
(Date:3/2/2015)... Cutler Integrative Medicine a leader in bringing innovative naturopathic ... to bring about self-renewal. A 30 day detox is ... cleaning house. According to Dr. Cutler, expert in ... environmental toxins like heavy metals, people’s food now becoming ... levels, we all have a level of toxic burden. ...
(Date:3/2/2015)... A cocaine snorting Oscar statue in ... nip slip or scathing scuffle. A new take on ... streets of Hollywood as Paper Jesus’ rendition of the ... substance abuse in Hollywood. The Oscar statue is depicted ... stance on the travails of drug addiction in Hollywood. ...
(Date:3/2/2015)... Clearwater, FL (PRWEB) March 02, 2015 ... comply with Title VI of the Civil Rights Act, ... (LEP) and hearing loss are bringing light to the ... Bureau statistics reveal that nearly 1 in 20 U.S. ... 1 in 10 in some major cities.(1) Stratus ...
(Date:3/2/2015)... Robins & Morton Celebrates Women In ... in Construction Week (March 1-7, sponsored by the National ... Women’s History Month, Robins & Morton is recognizing several ... and the construction industry as a whole. From the ... of roles in between, each woman has a story ...
(Date:3/2/2015)... March 02, 2015 Over the last ... among leading vendors seeking to expand their geographic presence ... is expected to reach $6.2 billion by 2019 at ... America including the U.S. and Canada and a major ... However developing regions such as Asia-Pacific including China and ...
Breaking Medicine News(10 mins):Health News:Skin and Wellness Power Couple give Quick Tips to Self-Renewal for Spring 2Health News:Oscar Statue Snorting Cocaine Catches All Eyes in Hollywood, Ca 2Health News:Oscar Statue Snorting Cocaine Catches All Eyes in Hollywood, Ca 3Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 2Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 3Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 4Health News:Robins & Morton Recognizes Women In Construction 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3
... Aug. 28, 2007 Dietary restrictions or other ... transplants more effective, UT Southwestern Medical Center researchers report. ... pancreatic islet cells transplanted into the liver fail not ... overexposure to toxic fats that are synthesized by the ...
... be available an open question, researcher says , , MONDAY, ... cardiac arrest while on school grounds, it makes the evening ... property is rare, and most of the victims are adults, ... service calls in the Seattle area, researchers found that faculty ...
... spend part of the Labor Day weekend complaining about their ... their jobs, a new University of Chicago study shows. ... with workers over 65 among the most satisfied. The ... 1972 and 2006 said they were satisfied at their jobs, ...
... A landmark study by University of Western Sydney researchers ... suffer fewer fractures and enjoy a better quality of ... calcium or calcium and vitamin D supplements, conducted by ... been published this week in the prestigious international medical ...
... survival, functioning may have been solved in rat experiments ... rats show that human embryonic stem cells can repair ... progression of heart failure. , Using stem cells to ... so far it has been fraught with problems. ...
... ears: Be sensible to avoid skin irritation , FRIDAY, Aug. ... that it,s almost like an addiction. , "For many people, it ... they,ve become so used to their lips having more moisture content ... at Baylor Medical Center in Garland, Texas, said in a prepared ...
Cached Medicine News:Health News:Circulating fats kill transplanted pancreas cells, study shows 2Health News:Heart Attacks at School Involve More Adults Than Kids 2Health News:Heart Attacks at School Involve More Adults Than Kids 3Health News:Despite grumbling, most Americans say they are happy at work 2Health News:International study strengthens case for daily calcium pill 2Health News:Embryonic Stem Cells Repair Human Heart 2Health News:Embryonic Stem Cells Repair Human Heart 3